Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More
Xconomy
NOVEMBER 18, 2016
president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick. Speculation swirled this week around the incoming U.S.
40 
Let's personalize your content